A5038514239- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inhalation and Respiratory Drug Delivery
- Systemic Lupus Erythematosus Research
- Allergic Rhinitis and Sensitization
- Dementia and Cognitive Impairment Research
- Pharmaceutical studies and practices
- IL-33, ST2, and ILC Pathways
- Child and Adolescent Psychosocial and Emotional Development
- Pediatric health and respiratory diseases
- Rheumatoid Arthritis Research and Therapies
- School Health and Nursing Education
- Aging, Health, and Disability
- Alzheimer's disease research and treatments
- Pharmacological Effects of Natural Compounds
- Family Support in Illness
- Stroke Rehabilitation and Recovery
- Sarcoidosis and Beryllium Toxicity Research
- Intergenerational Family Dynamics and Caregiving
- Otitis Media and Relapsing Polychondritis
- Health and Wellbeing Research
- Occupational and environmental lung diseases
- Food Allergy and Anaphylaxis Research
AstraZeneca (United States)
2014-2022
AstraZeneca (Japan)
2018-2021
AstraZeneca (Brazil)
2020
Patient-Centered Outcomes Research Institute
2015
The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.
Estimates of idiopathic pulmonary fibrosis (IPF) incidence and prevalence from electronic databases without case validation may be inaccurate.Develop claims algorithms to identify IPF assess their positive predictive value (PPV) estimate in the United States.We developed three cases HealthCore Integrated Research Database. Sensitive specific were based on literature review consultation with clinical experts. PPVs assessed using medical records. A third algorithm used logistic regression...
BackgroundPatients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced by up 71% improved lung function, control, life vs placebo.ObjectiveThis analysis further assessed impact on patient-reported outcomes (PROs) in PATHWAY.MethodsAdults were randomized subcutaneous (70 mg every 4 weeks, 210 or 280 2 weeks) placebo for 52 weeks. PROs using...
Atopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).To evaluate the effects tralokinumab health-related QoL in patients moderate-to-severe AD using patient-reported outcomes.This was phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study adults AD. The received subcutaneous or placebo (1:1:1:1) every 2 weeks for 12 and class 3 topical corticosteroid cream ointment at least once daily from run-in to end follow-up. Patient-reported...
Background: Health-related quality of life (HRQoL) and productivity patients with confirmed severe asthma (SA) have not been well characterized in large, real-world populations. Purpose: To characterize SA impact on HRQoL, work productivity, activity impairment a cohort the United States (US). Methods: CHRONICLE is an observational study specialist-treated adults (≥ 18 years) US receiving biologics or maintenance systemic corticosteroids (mSCS), those persistently uncontrolled by high-dosage...
Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody reduces exacerbations and improves for patients eosinophilic asthma.The objective this study was evaluate improvements daily asthma-related health status outcomes following treatment benralizumab.Pooled results from the SIROCCO (NCT01928771) CALIMA (NCT01914757)...
SLE significantly impairs health-related quality of life (HRQoL). In this post hoc analysis, structural equation modelling was used to examine the 'causal cascade' interaction between anifrolumab, disease activity and patient-reported outcomes (PROs) in pooled data from phase 3 TULIP-1 TULIP-2 trials.
Objective: To validate the Caregiver-Perceived Burden Questionnaire (CPBQ) and report its psychometric properties. Methods: The CPBQ was administered to caregivers of patients with moderate-to-severe AD in a double-blind randomized trial comparing extended-release memantine placebo (n = 676). Measurement properties were analyzed using factor analysis, classical test theory, Rasch analysis. Results: Two subscales identified: Caregivers’ Assessment Patient (CAP) Themselves (CAT). reliability...
There are no validated patient diaries for evaluating respiratory symptoms in idiopathic pulmonary fibrosis (IPF).To evaluate the performance properties of chronic obstructive disease (COPD) Evaluating Respiratory Symptoms™ (E-RS™: COPD) measure patients with IPF.Concept elicitation and cognitive interviews were conducted IPF to content validity, including comprehensiveness, relevance, interpretability E-RS™ items this population. Secondary analyses clinical study data performed scoring...
Objective For patients with severe asthma (SA), overestimation of control may lead to poorer outcomes. The objective this study was assess concurrent patient and specialist assessments treatment effectiveness among a large US cohort SA patients.Methods CHRONICLE is an ongoing observational treated by subspecialists. Asthma assessed using the patient-completed Control Test™ (ACT™) clinical assessment control. Treatment measured Global Evaluation Effectiveness (GETE) completed...
The morning tends to be the most difficult time of day for many patients with chronic obstructive pulmonary disease (COPD) when symptoms can limit one's ability perform even simple activities. Morning have been linked higher levels work absenteeism, thereby increasing already substantial economic burden associated COPD. A validated patient-reported outcome (PRO) instrument designed capture will allow a more comprehensive approach evaluation treatment benefit in COPD clinical trials.A...
The Asthma Daytime Symptom Diary (ADSD) and the Nighttime (ANSD) were developed to meet need for standardized patient-reported measures of asthma symptoms assess treatment trial outcomes in adults adolescents.To determine scoring evaluate measurement properties ADSD/ANSD.Adolescents (12-17 years) (18+ with completed draft 8-item electronic versions ADSD/ANSD 10 days alongside Adult Daily Scales (AASDS) a Patient Global Impression Severity (PGIS). Using classical modern psychometric methods,...
This qualitative study assessed the experience of patients with chronic rhinosinusitis nasal polyposis (NP) to inform development a novel symptom diary for clinical use.Concept elicitation and cognitive interviews were conducted who had physician-verified diagnosis NP history intranasal corticosteroid use. Concepts identified via open-ended follow-up questions. Relative symptom/impact disturbance level was using scale 0 (not at all disturbing) 10 (extremely disturbing).Patients (n = 30)...
Abstract Background A patient reported outcome (PRO) instrument with evidence of validity and reliability for assessing symptoms eosinophilic gastritis (EG) gastroenteritis (EGE) is needed to measure treatment benefit in clinical trials. The aim this research develop an EG/EGE symptom PRO patients aged 12 above. Methods Symptom Assessment Gastrointestinal Eosinophilic Diseases (SAGED) was developed through a literature review, discussions expert clinicians, concept elicitation cognitive...
Beyond asthma-related quality of life (QOL), limited data are available for relationships between asthma control status and patients' subjective well-being. We assessed the associations degree with lung function different aspects well-being patients severe, uncontrolled asthma.
Patients with severe, uncontrolled asthma may experience symptoms that impair their ability to engage in activities and increase perceived feelings of stress tiredness. We evaluated treatment the humanized, anti-eosinophilic monoclonal antibody benralizumab on asthma-related activity impairment, stress,
Benralizumab is a humanized, anti-eosinophilic monoclonal antibody that improves exacerbations and daily symptoms in patients (pts) with severe, uncontrolled eosinophilic asthma. This study investigated the association of asthma symptom improvements activity impairment assessments quality life (QOL).